Cargando…

Complementary action of granulocyte macrophage colony-stimulating factor and interleukin-17A induces interleukin-23, receptor activator of nuclear factor-κB ligand, and matrix metalloproteinases and drives bone and cartilage pathology in experimental arthritis: rationale for combination therapy in rheumatoid arthritis

INTRODUCTION: Type 17 T helper cells and interleukin (IL)-17 play important roles in the pathogenesis of human and murine arthritis. Although there is a clear link between IL-17 and granulocyte macrophage colony-stimulating factor (GM-CSF) in the inflammatory cascade, details about their interaction...

Descripción completa

Detalles Bibliográficos
Autores principales: van Nieuwenhuijze, Annemarie E. M., van de Loo, Fons A., Walgreen, Birgitte, Bennink, Miranda, Helsen, Monique, van den Bersselaar, Liduine, Wicks, Ian P., van den Berg, Wim B., Koenders, Marije I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496892/
https://www.ncbi.nlm.nih.gov/pubmed/26081345
http://dx.doi.org/10.1186/s13075-015-0683-5
_version_ 1782380478660083712
author van Nieuwenhuijze, Annemarie E. M.
van de Loo, Fons A.
Walgreen, Birgitte
Bennink, Miranda
Helsen, Monique
van den Bersselaar, Liduine
Wicks, Ian P.
van den Berg, Wim B.
Koenders, Marije I.
author_facet van Nieuwenhuijze, Annemarie E. M.
van de Loo, Fons A.
Walgreen, Birgitte
Bennink, Miranda
Helsen, Monique
van den Bersselaar, Liduine
Wicks, Ian P.
van den Berg, Wim B.
Koenders, Marije I.
author_sort van Nieuwenhuijze, Annemarie E. M.
collection PubMed
description INTRODUCTION: Type 17 T helper cells and interleukin (IL)-17 play important roles in the pathogenesis of human and murine arthritis. Although there is a clear link between IL-17 and granulocyte macrophage colony-stimulating factor (GM-CSF) in the inflammatory cascade, details about their interaction in arthritic synovial joints are unclear. In view of the introduction of GM-CSF and IL-17 inhibitors to the clinic, we studied how IL-17 and GM-CSF orchestrate the local production of inflammatory mediators during experimental arthritis. METHODS: To allow detection of additive, complementary or synergistic effects of IL-17 and GM-CSF, we used two opposing experimental approaches: treatment of arthritic mice with neutralising antibodies to IL-17 and GM-CSF and local overexpression of these cytokines in naive synovial joints. Mice were treated for 2 weeks with antibodies against IL-17 and/or GM-CSF after onset of collagen-induced arthritis. Naive mice were injected intraarticularly with adenoviral vectors for IL-17 and/or GM-CSF, resulting in local overexpression. Joint inflammation was monitored by macroscopic scoring, X-rays and histology. Joint washouts, synovial cell and lymph node cultures were analysed for cytokines, chemokines and inflammatory mediators by Luminex analysis, flow cytometry and quantitative polymerase chain reaction. RESULTS: Combined therapeutic anti-IL-17 and anti-GM-CSF ameliorated arthritis progression, and joint damage was dramatically reduced compared with treatment with anti-IL-17 or anti-GM-CSF alone. Anti-IL-17 specifically reduced synovial IL-23 transcription, whereas anti-GM-CSF reduced transcription of matrix metalloproteinases (MMPs) and receptor activator of nuclear factor κB ligand (RANKL). Overexpression of IL-17 or GM-CSF in naive knee joints elicited extensive inflammatory infiltrate, cartilage damage and bone destruction. Combined overexpression revealed additive and synergistic effects on the production of MMPs, RANKL and IL-23 in the synovium and led to complete destruction of the joint structure within 7 days. CONCLUSIONS: IL-17 and GM-CSF differentially mediate the inflammatory process in arthritic joints and show complementary and local additive effects. Combined blockade in arthritic mice reduced joint damage not only by direct inhibition of IL-17 and GM-CSF but also by indirect inhibition of IL-23 and RANKL. Our results provide a rationale for combination therapy in autoinflammatory conditions, especially for patients who do not fully respond to inhibition of the separate cytokines.
format Online
Article
Text
id pubmed-4496892
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-44968922015-07-10 Complementary action of granulocyte macrophage colony-stimulating factor and interleukin-17A induces interleukin-23, receptor activator of nuclear factor-κB ligand, and matrix metalloproteinases and drives bone and cartilage pathology in experimental arthritis: rationale for combination therapy in rheumatoid arthritis van Nieuwenhuijze, Annemarie E. M. van de Loo, Fons A. Walgreen, Birgitte Bennink, Miranda Helsen, Monique van den Bersselaar, Liduine Wicks, Ian P. van den Berg, Wim B. Koenders, Marije I. Arthritis Res Ther Research Article INTRODUCTION: Type 17 T helper cells and interleukin (IL)-17 play important roles in the pathogenesis of human and murine arthritis. Although there is a clear link between IL-17 and granulocyte macrophage colony-stimulating factor (GM-CSF) in the inflammatory cascade, details about their interaction in arthritic synovial joints are unclear. In view of the introduction of GM-CSF and IL-17 inhibitors to the clinic, we studied how IL-17 and GM-CSF orchestrate the local production of inflammatory mediators during experimental arthritis. METHODS: To allow detection of additive, complementary or synergistic effects of IL-17 and GM-CSF, we used two opposing experimental approaches: treatment of arthritic mice with neutralising antibodies to IL-17 and GM-CSF and local overexpression of these cytokines in naive synovial joints. Mice were treated for 2 weeks with antibodies against IL-17 and/or GM-CSF after onset of collagen-induced arthritis. Naive mice were injected intraarticularly with adenoviral vectors for IL-17 and/or GM-CSF, resulting in local overexpression. Joint inflammation was monitored by macroscopic scoring, X-rays and histology. Joint washouts, synovial cell and lymph node cultures were analysed for cytokines, chemokines and inflammatory mediators by Luminex analysis, flow cytometry and quantitative polymerase chain reaction. RESULTS: Combined therapeutic anti-IL-17 and anti-GM-CSF ameliorated arthritis progression, and joint damage was dramatically reduced compared with treatment with anti-IL-17 or anti-GM-CSF alone. Anti-IL-17 specifically reduced synovial IL-23 transcription, whereas anti-GM-CSF reduced transcription of matrix metalloproteinases (MMPs) and receptor activator of nuclear factor κB ligand (RANKL). Overexpression of IL-17 or GM-CSF in naive knee joints elicited extensive inflammatory infiltrate, cartilage damage and bone destruction. Combined overexpression revealed additive and synergistic effects on the production of MMPs, RANKL and IL-23 in the synovium and led to complete destruction of the joint structure within 7 days. CONCLUSIONS: IL-17 and GM-CSF differentially mediate the inflammatory process in arthritic joints and show complementary and local additive effects. Combined blockade in arthritic mice reduced joint damage not only by direct inhibition of IL-17 and GM-CSF but also by indirect inhibition of IL-23 and RANKL. Our results provide a rationale for combination therapy in autoinflammatory conditions, especially for patients who do not fully respond to inhibition of the separate cytokines. BioMed Central 2015-06-17 2015 /pmc/articles/PMC4496892/ /pubmed/26081345 http://dx.doi.org/10.1186/s13075-015-0683-5 Text en © van Nieuwenhuijze et al. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
van Nieuwenhuijze, Annemarie E. M.
van de Loo, Fons A.
Walgreen, Birgitte
Bennink, Miranda
Helsen, Monique
van den Bersselaar, Liduine
Wicks, Ian P.
van den Berg, Wim B.
Koenders, Marije I.
Complementary action of granulocyte macrophage colony-stimulating factor and interleukin-17A induces interleukin-23, receptor activator of nuclear factor-κB ligand, and matrix metalloproteinases and drives bone and cartilage pathology in experimental arthritis: rationale for combination therapy in rheumatoid arthritis
title Complementary action of granulocyte macrophage colony-stimulating factor and interleukin-17A induces interleukin-23, receptor activator of nuclear factor-κB ligand, and matrix metalloproteinases and drives bone and cartilage pathology in experimental arthritis: rationale for combination therapy in rheumatoid arthritis
title_full Complementary action of granulocyte macrophage colony-stimulating factor and interleukin-17A induces interleukin-23, receptor activator of nuclear factor-κB ligand, and matrix metalloproteinases and drives bone and cartilage pathology in experimental arthritis: rationale for combination therapy in rheumatoid arthritis
title_fullStr Complementary action of granulocyte macrophage colony-stimulating factor and interleukin-17A induces interleukin-23, receptor activator of nuclear factor-κB ligand, and matrix metalloproteinases and drives bone and cartilage pathology in experimental arthritis: rationale for combination therapy in rheumatoid arthritis
title_full_unstemmed Complementary action of granulocyte macrophage colony-stimulating factor and interleukin-17A induces interleukin-23, receptor activator of nuclear factor-κB ligand, and matrix metalloproteinases and drives bone and cartilage pathology in experimental arthritis: rationale for combination therapy in rheumatoid arthritis
title_short Complementary action of granulocyte macrophage colony-stimulating factor and interleukin-17A induces interleukin-23, receptor activator of nuclear factor-κB ligand, and matrix metalloproteinases and drives bone and cartilage pathology in experimental arthritis: rationale for combination therapy in rheumatoid arthritis
title_sort complementary action of granulocyte macrophage colony-stimulating factor and interleukin-17a induces interleukin-23, receptor activator of nuclear factor-κb ligand, and matrix metalloproteinases and drives bone and cartilage pathology in experimental arthritis: rationale for combination therapy in rheumatoid arthritis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496892/
https://www.ncbi.nlm.nih.gov/pubmed/26081345
http://dx.doi.org/10.1186/s13075-015-0683-5
work_keys_str_mv AT vannieuwenhuijzeannemarieem complementaryactionofgranulocytemacrophagecolonystimulatingfactorandinterleukin17ainducesinterleukin23receptoractivatorofnuclearfactorkbligandandmatrixmetalloproteinasesanddrivesboneandcartilagepathologyinexperimentalarthritisrationaleforcombinationtherap
AT vandeloofonsa complementaryactionofgranulocytemacrophagecolonystimulatingfactorandinterleukin17ainducesinterleukin23receptoractivatorofnuclearfactorkbligandandmatrixmetalloproteinasesanddrivesboneandcartilagepathologyinexperimentalarthritisrationaleforcombinationtherap
AT walgreenbirgitte complementaryactionofgranulocytemacrophagecolonystimulatingfactorandinterleukin17ainducesinterleukin23receptoractivatorofnuclearfactorkbligandandmatrixmetalloproteinasesanddrivesboneandcartilagepathologyinexperimentalarthritisrationaleforcombinationtherap
AT benninkmiranda complementaryactionofgranulocytemacrophagecolonystimulatingfactorandinterleukin17ainducesinterleukin23receptoractivatorofnuclearfactorkbligandandmatrixmetalloproteinasesanddrivesboneandcartilagepathologyinexperimentalarthritisrationaleforcombinationtherap
AT helsenmonique complementaryactionofgranulocytemacrophagecolonystimulatingfactorandinterleukin17ainducesinterleukin23receptoractivatorofnuclearfactorkbligandandmatrixmetalloproteinasesanddrivesboneandcartilagepathologyinexperimentalarthritisrationaleforcombinationtherap
AT vandenbersselaarliduine complementaryactionofgranulocytemacrophagecolonystimulatingfactorandinterleukin17ainducesinterleukin23receptoractivatorofnuclearfactorkbligandandmatrixmetalloproteinasesanddrivesboneandcartilagepathologyinexperimentalarthritisrationaleforcombinationtherap
AT wicksianp complementaryactionofgranulocytemacrophagecolonystimulatingfactorandinterleukin17ainducesinterleukin23receptoractivatorofnuclearfactorkbligandandmatrixmetalloproteinasesanddrivesboneandcartilagepathologyinexperimentalarthritisrationaleforcombinationtherap
AT vandenbergwimb complementaryactionofgranulocytemacrophagecolonystimulatingfactorandinterleukin17ainducesinterleukin23receptoractivatorofnuclearfactorkbligandandmatrixmetalloproteinasesanddrivesboneandcartilagepathologyinexperimentalarthritisrationaleforcombinationtherap
AT koendersmarijei complementaryactionofgranulocytemacrophagecolonystimulatingfactorandinterleukin17ainducesinterleukin23receptoractivatorofnuclearfactorkbligandandmatrixmetalloproteinasesanddrivesboneandcartilagepathologyinexperimentalarthritisrationaleforcombinationtherap